Azzalure 125IU (2 Vials)

General Information

Azzalure is a botulinum toxin type-A specifically designed for use in aesthetic indications. Azzalure is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at frown, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.

Indications for Azzalure Injections

In order to know that Azzalure-treated patients won’t experience any severe discomfort or unfortunate adverse reactions, it is crucial to have a pre-appointment before the injection session to discuss their goals and medical history. Only in this way, it will be possible to make sure the whole process will be safe and efficient.

Who can choose Azzalure as their muscle relaxant?

• People who need treatment of glabellar lines and lateral canthal lines;
• Take care of crow’s feet and small wrinkles in the eye area;
• Get rid of deep frown lines;
• And so on.

Treatment interval depends on the speed of one’s organism (namely, how much time is needed for nerve endings to “wake up” and muscles to start contracting again). In general, specialists recommend having an injection session every three to four months to make sure younger-looking skin is preserved.

Contraindications

Contraindications of Azzalure:

• Hypersensitivity to the active substance or to any of the excipients
• Presence of infection at the proposed injection sites
• Presence of myasthenia gravis, Eaton Lambert Syndrome or amyotrophic lateral sclerosis

Who should not use Azzalure?

• Pregnant and lactating women should not use this product as not enough clinical data has been collected to suggest that it is safe. There is a risk of this product passing through the mother to her baby
  Any individuals that develop hypersensitivity or an allergic reaction to the product should also refrain from using it. Children under 18 and adults over 65 should also not use this product
• Anyone with an infection on the skin surface at the proposed injection site should wait for the infection to completely disappear first
• There is a probable muscle weakness(myasthenia gravis) already present then do not use Azzalure either. The following diseases and conditions should also rule out the use of this medicine: Eaton Lambert syndrome and amyotrophic lateral sclerosis (degenerative nerve muscle disorder)

Side Effects

In some cases, Azzalure leads to the appearance of certain side effects. Among the most common suspected adverse reactions to the product are:

• Localised muscle weakness around the treatment area;
• Common injection site reactions of the skin (including redness, itching, and swelling);
• Temporary paresis of facial muscles proximal to areas of the treatment;
• Light bruising around the proposed injection sites;
• Headache;
• Nausea;
• Pain or discomfort;
• And so on.

Moreover, a vast majority of patients who have undergone an injection of Azzalure claim to experience exaggerated muscle weakness for the first several days after the treatment.

Just like excessive muscle weakness, most frequent undesirable reactions that are mentioned above tend to disappear on their own within one week after the treatment and do not require any medical supervision.

Storage Conditions

The product should be stored within the temperature range between 2 and 8 degrees Celcius

Buy Azzalure without license online

Looking where to buy Azzalure without license online? You are in the right place. We are a reliable distributor of cosmetic drugs on the market with many years of experience and thousands of satisfied customers.

• Broad range of products
• Affordable prices
• Flexible discounts
• Fast shipping
• Fast delivery
• Friendly sales managers

Feel free to buy Azzalure 125U and a wide range of other medical and cosmetic injectables at ISLA Cosmetology. This way, you will be able to take advantage of authentic products, affordable prices, and reliable delivery.

• EMC: https://www.medicines.org.uk/emc/product/6584
• Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.6584.pdf